Hepatic OATP1B zonal distribution: Implications for rifampicin‐mediated drug–drug interactions explored within a PBPK framework
CPT: Pharmacometrics & Systems Pharmacology · 2024
DOI: 10.1002/psp4.13188 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Mattie Hartauer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill,…. Hauptthemen laut MEDLINE: Rifampin, Drug Interactions, Liver-Specific Organic Anion Transporter 1, Pravastatin. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
OATP1B facilitates the uptake of xenobiotics into hepatocytes and is a prominent target for drug–drug interactions (DDIs). Reduced systemic exposure of OATP1B substrates has been reported following multiple‐dose rifampicin; one explanation for this observation is OATP1B induction. Non‐uniform hepatic distribution of OATP1B may impact local rifampicin tissue concentrations and rifampicin‐mediated protein induction, which may affect the accuracy of transporter‐ and/or metabolizing enzyme‐mediated DDI predictions. We incorporated quantitative zonal OATP1B distribution data from immunofluorescence imaging into a PBPK modeling framework to explore rifampicin interactions with OATP1B and CYP substrates. PBPK models were developed for rifampicin, two OATP1B substrates, pravastatin and repaglinide (also metabolized by CYP2C8/CYP3A4), and the CYP3A probe, midazolam. Simulated hepatic uptake of pravastatin and repaglinide increased from the periportal to the pericentral region (approximately 2.1‐fold), consistent with OATP1B distribution data. Simulated rifampicin unbound intracellular concentrations increased in the pericentral region (1.64‐fold) compared to simulations with uniformly distributed OATP1B. The absolute average fold error of the rifampicin PBPK model for predicting substrate maximal concentration ( C max ) and area under the plasma concentration–time curve (AUC) ratios was 1.41 and 1.54, respectively (nine studies). In conclusion, hepatic OATP1B distribution has a considerable impact on simulated zonal substrate uptake clearance values and simulated intracellular perpetrator concentrations, which regulate transporter and metabolic DDIs. Additionally, accounting for rifampicin‐mediated OATP1B induction in parallel with inhibition improved model predictions. This study provides novel insight into the effect of hepatic OATP1B distribution on site‐specific DDI predictions and the impact of accounting for zonal transporter distributions within PBPK models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Simcyp Division, Certara UK Ltd, Sheffield, UK.
ORCID-Profile: Mattie Hartauer, William A Murphy, Kim L R Brouwer, Roz Southall, Sibylle Neuhoff
Förderung
- NIGMS NIH HHS
Zitieren
APA
Hartauer, M., Murphy, W. A., Brouwer, K. L. R., Southall, R., & Neuhoff, S. (2024). Hepatic OATP1B zonal distribution: Implications for rifampicin‐mediated drug–drug interactions explored within a PBPK framework. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13188
Vancouver
Hartauer M, Murphy WA, Brouwer KLR, Southall R, Neuhoff S. Hepatic OATP1B zonal distribution: Implications for rifampicin‐mediated drug–drug interactions explored within a PBPK framework. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13188
BibTeX
@article{Hartauer2024,
author = {Hartauer, Mattie and Murphy, William A and Brouwer, Kim L R and Southall, Roz and Neuhoff, Sibylle},
title = {Hepatic OATP1B zonal distribution: Implications for rifampicin‐mediated drug–drug interactions explored within a PBPK framework},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2024},
doi = {10.1002/psp4.13188}
}
EUVIMED